logo
Plus   Neg
Share
Email

Amgen To Acquire 20.5% Stake In BeiGene For Approx. $2.7 Bln - Quick Facts

Amgen (AMGN) has entered into a strategic collaboration with BeiGene that will accelerate Amgen's plans to expand its oncology presence in China. BeiGene is a research-based, oncology-focused biotechnology company. Amgen will acquire a 20.5 percent stake in BeiGene for approximately $2.7 billion. This represents a purchase price of $174.85 per BeiGene American Depositary Share on NASDAQ.

Amgen and BeiGene will collaborate to advance 20 medicines from Amgen's oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion. Amgen will pay royalties to BeiGene on the sales of these products outside of China.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director... Shares of Upscale furniture chain RH (RH) are on a tear, on the heels of an upbeat annual forecast. Today, the stock set a new all-time high of $239.88.The stock is up more than 20% from its Dec 3 opening price of $196.66, and currently trading at $237.8, and nearly three-times its 52-week low of $84.11....
Follow RTT
>